Phase 3 clinical results of ready-to-use T cell therapy positively and significantly improve patient survival

On November 4, 2021, Atara Biotherapeutics announced that T cell immunotherapy tabelecleucel (tab-cel) is a critical phase 3 in the treatment of EB virus (EBV)-related post-transplant lymphoproliferative disease (EBV+PTLD) Positive results in clinical trials

EBV+PTLD is a type of lymphoma, a serious blood cancer, which may occur after solid organ transplantation (SOT) or allogeneic hematopoietic cell transplantation (HCT)

Tab-cel is a ready-to-use allogeneic T cell immunotherapy

In this ongoing Phase 3 trial, as of May 2021, 38 evaluable patients (24 after SOT and 14 after HCT) have observed an average ORR of 50% (19/38, 95% CI: 33.

▲Tab-cel Phase 3 clinical trial results (picture source: Atara Biotherapeutics official website)

Among the 19 patients who achieved remission, 11 had a duration of remission (DOR) of more than 6 months, and the median DOR had not yet been reached

The safety aspect is consistent with previously published data, and no new signals or problems have been reported

Reference materials:

[1] Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data.

(The original text has been deleted)